Theriva Biologics Inc (TOVX)

$0.37

Market is closed - opens 7 PM, 21 May 2024

Insights on Theriva Biologics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 54.7% return, outperforming this stock by 100.2%

Performance

  • $0.37
    $0.38
    $0.37
    downward going graph

    0.0%

    Downside

    Day's Volatility :3.65%

    Upside

    3.65%

    downward going graph
  • $0.20
    $1.20
    $0.37
    downward going graph

    46.7%

    Downside

    52 Weeks Volatility :83.57%

    Upside

    69.17%

    downward going graph

Returns

PeriodTheriva Biologics IncIndex (Russel 2000)
3 Months
-20.62%
0.0%
6 Months
-17.62%
0.0%
1 Year
-45.49%
0.0%
3 Years
-64.03%
-19.9%

Highlights

Market Capitalization
6.5M
Book Value
$1.83
Earnings Per Share (EPS)
-1.14
Wall Street Target Price
4.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-23.91%
Return On Equity TTM
-44.94%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-22.2M
Diluted Eps TTM
-1.14
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.2
EPS Estimate Next Year
-1.15
EPS Estimate Current Quarter
-0.34
EPS Estimate Next Quarter
-0.28

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Theriva Biologics Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1116.22%

Current $0.37
Target $4.50

Technicals Summary

Sell

Neutral

Buy

Theriva Biologics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Theriva Biologics Inc
Theriva Biologics Inc
-9.81%
-17.62%
-45.49%
-64.03%
-64.03%
Moderna, Inc.
Moderna, Inc.
27.23%
68.31%
4.86%
-19.93%
488.05%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
9.12%
22.54%
30.71%
91.4%
224.65%
Novo Nordisk A/s
Novo Nordisk A/s
5.29%
27.32%
54.69%
226.34%
458.15%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
11.32%
24.76%
30.96%
105.54%
168.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Theriva Biologics Inc
Theriva Biologics Inc
NA
NA
NA
-1.2
-0.45
-0.24
NA
1.83
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.04
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.57
28.57
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.03
46.03
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.58
28.58
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Theriva Biologics Inc
Theriva Biologics Inc
Buy
$6.5M
-64.03%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$50.8B
488.05%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$106.7B
224.65%
28.57
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$593.5B
458.15%
46.03
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$113.7B
168.64%
28.58
39.46%

Company Information

synthetic biologics, inc. (nyse mkt: syn) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. the company's lead candidates poised for phase 3 development are: (1) syn-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (ibs-c), and (2) syn-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (iv) beta-lactam antibiotics for the prevention of c. difficile infection (cdi), antibiotic-associated diarrhea (aad) and the emergence of antimicrobial-resistance (amr). the company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (pku).

Organization
Theriva Biologics Inc
Employees
22
CEO
Mr. Steven A. Shallcross CPA
Industry
Miscellaneous

FAQs